Zoledronic acid in vivo increases in vitro proliferation of rat mesenchymal stromal cells

Show full item record



Permalink

http://hdl.handle.net/10138/167442

Citation

Heino , T J , Alm , J J , Halkosaari , H J & Välimäki , V-V 2016 , ' Zoledronic acid in vivo increases in vitro proliferation of rat mesenchymal stromal cells ' Acta Orthopaedica , vol. 87 , no. 4 , pp. 412-417 . DOI: 10.1080/17453674.2016.1188258

Title: Zoledronic acid in vivo increases in vitro proliferation of rat mesenchymal stromal cells
Author: Heino, Terhi J.; Alm, Jessica J.; Halkosaari, Heikki J.; Välimäki, Ville-Valtteri
Contributor: University of Helsinki, I kirurgian klinikka (Töölö)
Date: 2016-08
Language: eng
Number of pages: 6
Belongs to series: Acta Orthopaedica
ISSN: 1745-3674
URI: http://hdl.handle.net/10138/167442
Abstract: Background and purpose-Bisphosphonates are widely used in the treatment of bone loss, but they might also have positive effects on osteoblastic cells and bone formation. We evaluated the effect of in vivo zoledronic acid (ZA) treatment and possible concomitant effects of ZA and fracture on the ex vivo osteogenic capacity of rat mesenchymal stromal cells (MSCs). Methods-A closed femoral fracture model was used in adult female rats and ZA was administered as a single bolus or as weekly doses up to 8 weeks. Bone marrow MSCs were isolated and cultured for in vitro analyses. Fracture healing was evaluated by radiography, micro -computed tomography (mu CT), and histology. Results-Both bolus and weekly ZA increased fracture-site bone mineral content and volume. MSCs from weekly ZA-treated animals showed increased ex vivo proliferative capacity, while no substantial effect on osteoblastic differentiation was observed. Fracture itself did not have any substantial effect on cell proliferation or differentiation at 8 weeks. Serum biochemical markers showed higher levels of bone formation in animals with fracture than in intact animals, while no difference in bone resorption was observed. Interestingly, ex vivo osteoblastic differentiation of MSCs was found to correlate with in vivo serum bone markers. Interpretation-Our data show that in vivo zoledronic acid treatment can influence ex vivo proliferation of MSCs, indicating that bisphosphonates can have sustainable effects on cells of the osteoblastic lineage. Further research is needed to investigate the mechanisms.
Subject: POSTMENOPAUSAL OSTEOPOROSIS
BISPHOSPHONATE INCADRONATE
BONE HISTOMORPHOMETRY
STEM-CELLS
FRACTURE
DIFFERENTIATION
OSTEOBLAST
ALENDRONATE
MATURATION
3126 Surgery, anesthesiology, intensive care, radiology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
17453674.2016.pdf 2.602Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record